U.S. market Closed. Opens in 5 hours 33 minutes

SAGE | Sage Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 6.71 - 7.11
52 Week Range 4.62 - 27.68
Beta 0.22
Implied Volatility 110.85%
IV Rank 29.20%
Day's Volume 2,058,251
Average Volume 1,555,731
Shares Outstanding 61,173,300
Market Cap 424,542,702
Sector Healthcare
Industry Biotechnology
IPO Date 2014-07-18
Valuation
Profitability
Growth
Health
P/E Ratio -1.25
Forward P/E Ratio -3.95
EPS -5.57
1YR Price Target 48.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 487
Country USA
Website SAGE
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.
*Chart delayed
Analyzing fundamentals for SAGE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see SAGE Fundamentals page.

Watching at SAGE technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on SAGE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙